DSM-Firmenich has developed a novel 3D facial skin microbiome mapping technology, which the Dutch-Swiss firm says is set to unlock a new generation of cosmetic innovations.
Published in Journal of Investigative Dermatology, ‘3D Facial Skin Microbiome Mapping: An Integrated Technology for Continuous Visualization of Absolute Microbial Densities’ addresses long-standing limitations in microbiome research.
While traditional approaches rely on relative abundance data from a limited number of sampling points, this proof-of-concept introduces absolute quantification of 26 bacterial and fungal species across 24 facial sites, combined with AI models.
Using a smooth interpolation method, the team created the first continuous 3D maps of the facial microbiome, offering a holistic and high-resolution view of microbial topography.
DSM-Firmenich says the research has delivered several important breakthroughs, including high-resolution, continuous 3D mapping that enables an intuitive and comprehensive view of microbial distribution across facial skin.
The study also reveals spatially distinct bacterial–fungal interactions, including potential competitive dynamics between Malassezia restricta and Cutibacterium acnes.
In addition, machine learning models have demonstrated that a reduced set of sampling sites—down to nine—can accurately capture microbiome variability, with the central forehead emerging as a key predictive location.
The technology also creates new opportunities to monitor microbiome-modulating treatments, design targeted interventions for dysbiosis, and link microbial data with skin physiology.
DSM-Firmenich said the research opens the door to new industry collaborations.
“We invite partners, customers, and members of the scientific community to build on this work with us,” it said.
“Together, we can further explore the spatial interactions between cosmetic actives and the skin microbiome, advancing microbiome-centred innovation and substantiating differentiated and future-forward claims.”
